This review examines the role of genetic mutations in immune response and microenvironment in acute myeloid leukemia, highlighting implications for future immunotherapies.
Key Points
Genetic mutations in AML significantly influence immune responses, with specific alterations altering the immune microenvironment.
The review highlights several key mutations in AML, including FLT3-ITD, NPM1, and TP53, impacting immune infiltration and tumor progression.
Immunotherapies targeting neoepitopes derived from AML driver mutations may enhance anti-tumor responses and overcome immune escape.
Understanding the balance of immune activation and suppression in AML could lead to more effective and tailored immunotherapy approaches.